Related coverage linked through entity extraction aliases.
Apr 20, 2026
Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.
Mar 07, 2026
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.
Mar 05, 2026
Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.
